Phase II study demonstrating failure of both a five-drug continuous-therapy regimen and a two-drug pulse-therapy regimen in the treatment of metastatic neuroblastoma: Southwest Oncology Group Study 822.

Abstract

Twenty-six children greater than 1 year of age with previously untreated stage IV neuroblastoma were randomized to receive either a five-drug regimen (prednisone, cyclophosphamide, actinomycin D, vincristine, and daunorubicin) or a two-drug regimen (cyclophosphamide and vincristine). Complete response rates were 6% and 9% for the five-drug and the two-drug regimens respectively. Partial response rates were 13% and 27% for the five-drug and the two-drug regimens respectively. The mean duration of the seven responses was 9 months, and all 26 patients had died within 2 years. Neither regimen was effective for long-term disease control in these children with neuroblastoma.

• Authors: E J Doering, R Nitschke, M E Haggard, V J Land, S K Morgan, K Starling, T Williams, S George
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 63 Issue 8 Pg. 1383-4 (Aug 1979) ISSN: 0361-5960 [Print] United States
• PMID: 476711 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Dactinomycin
• Vincristine
• Cyclophosphamide
• Prednisone
• Daunorubicin

Topics

• Antineoplastic Agents (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Dactinomycin (administration & dosage)
• Daunorubicin (administration & dosage)
• Drug Evaluation
• Drug Therapy, Combination
• Humans
• Infant
• Neuroblastoma (drug therapy, secondary)
• Prednisone (administration & dosage)
• Vincristine (administration & dosage)